Pricing

BAKER BROS. ADVISORS LP

55 followers · 13 likes
NEW YORK NY Investment Advisor Hedge Fund Activist Investor
13F Summary

Subscription Required

Equal-WT
WhaleScore 2.0 ?

85

S&P 500
WhaleScore ?

Subscription Required

Equal-WT
WhaleScore 1.0 ?

Baker Bros. Advisors is based out of New York. Baker Bros. Advisors is a hedge fund with 2 clients and discretionary assets under management (AUM) of $21,976,239,930 (Form ADV from 2024-03-28). Their last reported 13F filing for Q1 2025 included $9,036,702,464 in managed 13F securities and a top 10 holdings concentration of 81.82%. Baker Bros. Advisors's largest holding is BeiGene Ltd with shares held of 8,799,053. Whalewisdom has at least 94 13F filings, 208 13D filings, 296 13G filings, and 160 Form 4 filings
Business Description
Baker Bros. Advisors LP ("BBA") may tailor its advisory services to clients if certain investments cannot be held for legal, tax, portfolio concentration, or other investment-based reasons. While BBA utilizes a similar strategy for all of its Funds, it does not tailor its advisory services to the needs of individual investors in the Funds nor accepts Investor-imposed investment restrictions other than the Investment Limits. BBA has established, and may in the future establish additional, managed accounts or single investor funds for large or strategic investors. The advisory agreements for such managed accounts or funds will generally be subject to different terms than the Funds, including but not limited to liquidity, investment objectives, guidelines and restrictions, fees and other terms.
Investment Strategy
BBA is a discretionary asset management firm that employs a fundamentally-driven approach to life sciences investing. They typically invest in large, concentrated positions in life sciences companies with the potential for significant value creation over the long term. These positions can represent a significant portion of the capital structure of the companies they invest in, and BBA often engages in active dialogue with the management of those companies. BBA does not diversify the Funds’ portfolios for the purpose of achieving diversification. Instead, each investment may constitute a significant portion of a Fund's assets under management. Due to its large, concentrated, and relatively long-term investment strategy, as well as the volatile nature of the securities within its investible universe, BBA anticipates that the Funds’ returns will be volatile and uncertain.
Owners
  • BAKER BROS. ADVISORS (GP), LLC - GENERAL PARTNER
  • BAKER, JULIAN, CHARLES - LIMITED PARTNER
  • LESSING, SCOTT, LAWRENCE - PRESIDENT, CHIEF COMPLIANCE OFFICER
  • TOOHEY, ALEXANDRA, ANN - CHIEF FINANCIAL OFFICER
  • BAKER, FELIX, JAMES - LIMITED PARTNER
  • Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)

2025-03-31

Top Buys (13F)

Name % Change
INSM Insmed Inc 0.85%
IMVT Immunovant Inc 0.58%
ALKS Alkermes Plc 0.35%
IMCR Immunocore Holdings 0.29%
PCVX Vaxcyte, Inc 0.23%

2025-03-31

Top Sells (13F)

2025-03-31

13F Holdings Summary

Name $ Change
ONC BeiGene Ltd 26.5%
INCY Incyte Corp. 20.6%
ACAD Acadia Pharmaceutica 7.88%
MDGL Madrigal Pharmaceuti 7.24%
SMMT Summit Therapeutics 5.21%

2025-03-31

13F Activity

Market Value $9.04b, Prior: $9.36b
Inflows (Outflows) as % of Total MV (-2.2655)%
New Purchases 4 stocks
Added To 11 stocks
Sold out of 10 stocks
Reduced holdings in 16 stocks
Top 10 Holdings % 81.82%
Turnover %[1] 14.14%
Turnover Alt %[2] 2.28%
Time Held Top 20 14.15 quarters
Time Held Top 10 17.5 quarters
Time Held All 13.22 quarters

[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.

[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.

2025-03-31

13F Sector Allocation Over Time

limited to past 4 quarters. Subscribe to see all available data

2025-03-31

Analysis

Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31

Portfolio Performance